Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00088036
First received: July 19, 2004
Last updated: July 21, 2006
Last verified: July 2006

July 19, 2004
July 21, 2006
February 2004
Not Provided
  • To assess the efficacy of olanzapine therapy (5.0-10.0 mg/day) compared with placebo in patients with BPD,as defined by DSM-IV-TR criteria,
  • in improving overall symptomatology as measured by the last observation carried forward (LOCF) mean change from baseline to endpoint in the ZAN-BPD total score for up to 12 weeks of double-blind treatment.
Not Provided
Complete list of historical versions of study NCT00088036 on ClinicalTrials.gov Archive Site
  • To assess the efficacy of olanzapine 2.5 mg/day compared with placebo in patients with BPD, as defined by DSM-IV-TR criteria
  • in improving overall symptomatology as measured by last observation carried forward (LOCF) mean change from baseline to endpoint in the ZAN-BPD total score for up to 12 weeks of double-blind treatment
  • to evaluate the level of functioning as measured by LOCF mean change from baseline to endpoint on the Sheehan Disability Scale (Work, Social Life,and Family Life/Home Responsibilities)total score
  • and individual scores(Work, Social Life,Family Life/Home Responsibilities, Days Lost, and Days Under Productive)
  • to assess the reduction of aggression, suicidality, and irritability as measured by the LOCF mean change from baseline to endpoint in the rating of the Overt Aggression Scale-Modified (OAS-M) total score
  • to assess the reduction of self-mutilation determined by the mean frequency of self-mutilation attempts as captured on the Lifetime Self-Destructiveness scale (LSDS), which will measure both frequency and nature of attempts
  • The frequency of self-mutilation for each patient will be calculated as the number of self-mutilations divided by the patient's total number of study drug exposure
  • (Self-mutilation is defined as deliberate physical self harm without the intent to commit suicide)
  • to assess the reduction of suicide attempts as determined by the mean frequency of suicide attempts.
  • The frequency of suicide attempts for each patient will be calculated as the number of suicide attempts divided by the patient's total number of days of study drug exposure
  • to assess the treatment of the core domains of BPD as assessed by LOCF mean change from baseline to endpoint in each of the four ZAN-BPD domain scores (cognitive disturbances,disturbed relationships,affective disturbances,and impulsivity)
  • to assess the following symptom domains (paranoid ideation, psychoticism, anxiety, depression, anger/hostility, interpersonal sensitivity, phobic anxiety, obsessive-compulsive, and somatization)on the Global Severity Index of the SCL-90-R
  • as determined by the LOCF mean change from baseline to endpoint
  • to evaluate the rate of response, time in response, and time to response. Levels of response are defined as a 30% and 50% reduction in the ZAN-BPD total score from baseline (Visit 2)
  • to assess the treatment of depressive mood symptoms as measured by LOCF mean change from baseline to endpoint in the total score on the Montgomery-Asberg Depression Rating Scale (MADRS)
  • to assess the resource utilization by frequency divided by the patient's total number of days of study drug exposure for days hospitalized for physical and psychological reasons,number of hospital admissions
  • or medical visits(emergency department, general and special care physicians, and other mental health care professionals
  • to evaluate the level of functioning in patients as measured by LOCF mean change from baseline to endpoint on the GAF
  • to assess the safety as measured by treatment-emergency adverse events (TEAE), change in vital signs and laboratory analytes, electrocardiograms and severity of any extrapyramidal symptoms (EPS)
  • The Simpson Angus Scale, Abnormal Involuntary Movement Scale and Barnes Akathisia Scale will be used to measure EPS
  • The objectives of Study Period III (Open Label Extension Period are:
  • to assess the longer term safety of olanzapine for up to 12 additional weeks of therapy
  • as measured by TEAE, change in vital signs and laboratory analytes, ECG and severity of EPS.
  • to explore the efficacy of continued olanzapine treatment for up to 12 additional weeks of therapy
  • as measured by the ZAN-BPD total score, MADRS, Sheehan Disability Scale and LSDS
  • to assess resource utilization by frequency of divided by the patient's total number of days of study drug exposure for
  • days hospitalized for physical and psychological reasons, number of hospital admissions
  • or medical visits (emergency department, general and special care physicians or other mental health care professionals
Not Provided
Not Provided
Not Provided
 
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo

The purpose of the protocol is to evaluate the efficacy and safety of olanzapine compared with placebo in patients with Borderline Personality Disorder (BPD).

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Borderline Personality Disorder
Drug: Olanzapine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
450
January 2006
Not Provided

Inclusion Criteria:

  • Patients must be of outpatient status at Visit 1 and through Visit 2
  • Patients must be 18 through 65 years of age at Visit 1
  • Patients must meet all of the DSM-IV-TR General Diagnostic Criteria for a Personality Disorder AND Patients must meet DSM-IV-TR diagnostic criteria for BPD as determined by the DIPD-IV, confirmed by a psychiatrist with training in the evaluation and assessment of BPD.
  • The symptom severity as assessed by the total score of the ZAN-BPD, confirmed by a psychiatrist with training in the evaluation and assessment of BPD, must be greater than or equal to 9 at Visit 2.
  • Female patients of childbearing potential must test negative for pregnancy and must be using medically accepted means of contraception throughout the study. Use of any oral or injectable contraception must be initiated prior to Visit 2.

Exclusion Criteria:

  • Investigators, study site personnel directly affiliated with the study, or immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  • Persons employed by Lilly (that is, employees, temporary contract workers, or designees responsible for the conduct of the study). Immediate family of Lilly employees may participate in Lilly-sponsored clinical trials, but are not permitted to participate at a Lilly facility. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
  • Have previously participated (have been randomized) or withdrawn from this study or any other Lilly sponsored study investigating olanzapine.
  • Have had previous treatment with olanzapine unless, in the opinion of the investigator, the patient's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of olanzapine was confounded by concomitant medication.
  • Female patients who are either pregnant or nursing.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Turkey,   Argentina,   Poland,   Romania
 
NCT00088036
6253, F1D-MC-HGKK
Not Provided
Not Provided
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
July 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP